Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial-Reference-Cited by-同舟云学术

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

Published:2021-11 Issue: Volume: Page:
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Baciarello Giulia,Delva Remy,Gravis Gwenaelle,Tazi Youssef,Beuzeboc Philippe,Gross-Goupil Marine,Bompas Emmanuelle,Joly Florence,Greilsamer Charlotte,Hon Thierry Nguyen Tan,Barthelemy Philippe,Culine Stephane,Berdah Jean Francois,Deblock Mathilde,Ratta Raffaele,Flechon Aude,Cheneau Caroline,Maillard Aline,Martineau Geraldine,Borget Isabelle,Fizazi Karim^ORCID

Publisher

Elsevier BV

Subject

Urology

Reference16 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

2. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors;Vrignaud;Clin Cancer Res,2013

3. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer;van Soest;Eur Urol,2015

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA;Oudard;J Clin Oncol,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer;Current Oncology;2024-08-29

2. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis;BMC Cancer;2024-06-08

3. Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells;Cancer Cell;2024-04

4. Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions;BioChem;2023-08-29

5. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics;Frontiers in Oncology;2023-08-17